Bayer Aktiengesellschaft (BAYND.XC)
| Previous close | 29.48 |
| Open | 28.61 |
| Bid | 0.00 x 0 |
| Ask | 29.63 x 0 |
| Day's range | 28.60 - 28.61 |
| 52-week range | 24.99 - 54.41 |
| Volume | |
| Avg. volume | 907 |
| Market cap | 28.102B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.17 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | 0.11 (0.38%) |
| Ex-dividend date | 29 Apr 2024 |
| 1y target est | N/A |
BenzingaBayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Bayer AG (OTC:BAYRY) (OTC:BAYZF) will present detailed results from the Phase 3 studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms (hot flashes) associated with menopause compared to placebo. The company released the topline data showing elinzanetant met all four primary endpoints in both studies. These data will be presented at the 2024 American College of Obstetricians and Gynec
ZacksPharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
ZacksBayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
